MNG482
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.503
- COAGULATION+0.341
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.317
- ADIPOGENESIS+0.295
- CHOLESTEROL_HOMEOSTASIS+0.295
- ANGIOGENESIS+0.288
- FATTY_ACID_METABOLISM+0.263
- MYC_TARGETS_V2+0.262
- ALLOGRAFT_REJECTION+0.259
- PANCREAS_BETA_CELLS+0.246
Top 10 suppressed
- MITOTIC_SPINDLE-0.404
- PROTEIN_SECRETION-0.377
- G2M_CHECKPOINT-0.348
- E2F_TARGETS-0.245
- TGF_BETA_SIGNALING-0.245
- UV_RESPONSE_DN-0.229
- PI3K_AKT_MTOR_SIGNALING-0.153
- UNFOLDED_PROTEIN_RESPONSE-0.150
- TNFA_SIGNALING_VIA_NFKB-0.135
- SPERMATOGENESIS-0.112
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG589 | — | — | 0.839 |
| 2 | 9c8140ab-454c-4f62-aa6e-d1cfe4e498e0 | — | — | 0.819 |
| 3 | SRR25043613 | — | — | 0.806 |
| 4 | MDT-AP-2585 | Med | Medulloblastoma | 0.755 |
| 5 | 078de409-654a-4fef-80ce-f0d26b6a8cb1 | — | — | 0.743 |
| 6 | SJEPD001516_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.738 |
| 7 | 7dab0af8-ab64-4014-b7b7-bf0df59a1b3a | — | — | 0.732 |
| 8 | 966a66a2-8aac-41e8-8007-88fd92d2e8e8 | — | — | 0.730 |
| 9 | b83a1cf6-50a6-44fa-834d-8b3df88149fa | — | — | 0.724 |
| 10 | SRR2016959 | — | — | 0.722 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.503 | Remibrutinib | — uncovered |
| COAGULATION | 0.341 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.317 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.295 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.295 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.288 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.263 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.262 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.259 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.246 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.223 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.221 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.183 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.179 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.162 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.127 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.107 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.103 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.087 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.084 | Inavolisib | — uncovered |